Published in Br Heart J on November 01, 1980
Reduction of sudden deaths after myocardial infarction by treatment with alprenolol. Preliminary results. Lancet (1974) 4.40
QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation (1978) 3.32
The effect of propranolol (Inderal) on the electrocardiogram of normal subjects. Am Heart J (1969) 1.51
Sudden death and the idiopathic long Q-T syndrome. Am J Med (1979) 0.95
Familial Q-T prolongation syndrome. Convulsive seizures and paroxysmal ventricular fibrillation. Arch Neurol (1974) 0.90
QT time in patients treated with alprenolol or placebo after myocardial infarction. Br Heart J (1979) 0.83
The relationship between QT interval and ventricular arrhythmias in acute myocardial infarction. Acta Med Scand (1978) 0.83
STATs in oncogenesis. Oncogene (2000) 8.60
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 4.22
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96
Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest (2001) 3.79
STAT proteins: novel molecular targets for cancer drug discovery. Oncogene (2000) 3.75
Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A (2001) 3.29
Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem (2001) 3.27
Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J (2000) 2.90
Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet (1999) 2.84
AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol (2001) 2.81
Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ (1997) 2.63
In vitro transcription from the adenovirus 2 major late promoter utilizing templates truncated at promoter-proximal sites. J Biol Chem (1984) 2.58
Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J Biol Chem (1993) 2.17
Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09
Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene (2000) 2.06
Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart (2000) 2.05
Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res (1997) 1.97
Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol (1999) 1.80
Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci (1998) 1.77
Enzymatically inactive p60c-src mutant with altered ATP-binding site is fully phosphorylated in its carboxy-terminal regulatory region. Cell (1987) 1.71
Splicing pathways of SV40 mRNAs in X. laevis oocytes differ in their requirements for snRNPs. Cell (1984) 1.69
Genetic lesions involved in temperature sensitivity of the src gene products of four Rous sarcoma virus mutants. J Virol (1986) 1.64
Preconditioning effects of levosimendan in coronary artery bypass grafting--a pilot study. Br J Anaesth (2006) 1.64
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res (1998) 1.61
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem (2000) 1.61
Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene (1997) 1.48
The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem (1997) 1.45
Reconstitution of the multiprotein complex of pp60src, hsp90, and p50 in a cell-free system. J Biol Chem (1992) 1.42
Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene (1999) 1.41
Genetic analysis of p60v-src domains involved in the induction of different cell transformation parameters. J Virol (1986) 1.38
Cooperative regulation of Mcl-1 by Janus kinase/stat and phosphatidylinositol 3-kinase contribute to granulocyte-macrophage colony-stimulating factor-delayed apoptosis in human neutrophils. J Immunol (2001) 1.32
Thyrotrophin-induced aggregation and reorganization into follicles of isolated porcine-thyroid cells. 1. Mechanism of action of thyrotrophin and metabolic properties. Eur J Biochem (1971) 1.29
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood (1999) 1.29
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol (1997) 1.28
Characterization of avian and viral p60src proteins expressed in yeast. Proc Natl Acad Sci U S A (1987) 1.28
Role of the cytoplasmic tyrosines of beta 1A integrins in transformation by v-src. Proc Natl Acad Sci U S A (2001) 1.28
Role of tyrosine kinase activity of epidermal growth factor receptor in the lysophosphatidic acid-stimulated mitogen-activated protein kinase pathway. J Biol Chem (1998) 1.27
STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol (1999) 1.24
Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem (1997) 1.23
Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res (2001) 1.22
The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia (2010) 1.20
The membrane-binding domain and myristylation of p60v-src are not essential for stimulation of cell proliferation. J Virol (1987) 1.20
Twenty-five-year coronary mortality trends in the seven countries study using the accelerated failure time model. Eur J Epidemiol (2003) 1.19
Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity. Oncogene (2000) 1.16
GTPase-activating protein interactions with the viral and cellular Src kinases. Proc Natl Acad Sci U S A (1991) 1.11
Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck. J Virol (1997) 1.11
Twenty-five-year cardiovascular disease incidence among middle-aged men. Disease burden, time shape, predictors, risk probabilities. Ital Heart J (2000) 1.10
Raf-1 N-terminal sequences necessary for Ras-Raf interaction and signal transduction. Mol Cell Biol (1995) 1.09
Triiodothyronine binding to isolated liver cell nuclei. Endocrinology (1975) 1.08
Transcription initiation by RNA polymerase II is inhibited by S-adenosylhomocysteine. Proc Natl Acad Sci U S A (1982) 1.07
Triiodothyronine binding to liver nuclear solubilized proteins in vitro. Endocrinology (1975) 1.06
Molecular features of the viral and cellular Src kinases involved in interactions with the GTPase-activating protein. Mol Cell Biol (1991) 1.05
Assessment of flow velocity reserve by transthoracic Doppler echocardiography and venous adenosine infusion before and after left anterior descending coronary artery stenting. J Am Coll Cardiol (2001) 1.03
Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood (1999) 1.03
Biochemical properties of p60v-src mutants that induce different cell transformation parameters. J Virol (1986) 1.03
[Symptomatology of hydatid cyst of the heart. Study of a continuous series of 13 cases and value of x-ray computed tomography]. Arch Mal Coeur Vaiss (1985) 1.02
The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res (2000) 1.00
Pacemaker syndrome with DDD pacing. Pacing Clin Electrophysiol (1984) 1.00
Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet (1993) 0.99
A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase. J Biol Chem (1995) 0.98
Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest (1998) 0.97
Functional mapping of the N-terminal regulatory domain in the human Raf-1 protein kinase. J Biol Chem (1995) 0.97
Expression, purification and characterization of recombinant mitogen-activated protein kinase kinases. Biochem J (1994) 0.97
Activation of extracellular signal-regulated kinase (ERK) by mitogenic stimuli is repressed in v-Src-transformed cells. Cell Growth Differ (1997) 0.96
Two SH2 domains of p120 Ras GTPase-activating protein bind synergistically to tyrosine phosphorylated p190 Rho GTPase-activating protein. J Biol Chem (1995) 0.96
Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse. Am J Med (1982) 0.96
Activation of STAT3 by the c-Fes protein-tyrosine kinase. J Biol Chem (1998) 0.96
[Biosynthesis, iodination and heterogeneity of thyroglobulin]. Bull Soc Chim Biol (Paris) (1965) 0.95
Prediction of sudden death from QTc interval prolongation in patients with chronic ischemic heart disease. J Electrocardiol (1986) 0.95
The protein-protein complex between pp60v-src and hsp90 is stabilized by molybdate, vanadate, tungstate, and an endogenous cytosolic metal. J Biol Chem (1992) 0.95
Lack of induction of neuroretinal cell proliferation by Rous sarcoma virus variants that carry the c-src gene. Mol Cell Biol (1985) 0.95
Regulation of the junB gene by v-src. Mol Cell Biol (1992) 0.94
[Identification of eight new mutations in the c-erbAB gene of patients with resistance to thyroid hormone]. Ann Endocrinol (Paris) (2001) 0.94
Iodination and biosynthesis of rat thyroglobulin. Biochem Biophys Res Commun (1964) 0.93
Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential. Cell Growth Differ (1997) 0.93
The native v-Raf.hsp90.p50 heterocomplex contains a novel immunophilin of the FK506 binding class. J Biol Chem (1994) 0.92
Long-term follow-up of patients treated with VVI pacing and sequential pacing with special reference to VA retrograde conduction. Pacing Clin Electrophysiol (1988) 0.92
KATP channels and 'border zone' arrhythmias: role of the repolarization dispersion between normal and ischaemic ventricular regions. Br J Pharmacol (1999) 0.92
In vitro binding of triiodothyronine to rat liver mitochondria. Pflugers Arch (1981) 0.91
Torsion of the human left ventricle: experimental analysis and computational modeling. Prog Biophys Mol Biol (2011) 0.90
Attenuation of serum inducibility of immediate early genes by oncoproteins in tyrosine kinase signaling pathways. Mol Cell Biol (1993) 0.90
Regulation of glucocorticoid receptor function through assembly of a receptor-heat shock protein complex. Ann N Y Acad Sci (1993) 0.90
Calcitriol is a positive effector of adipose differentiation in the OB 17 cell line: relationship with the adipogenic action of triiodothyronine. Biochem Biophys Res Commun (1997) 0.89
Defective thyroglobulin export as a cause of congenital goitre. Clin Endocrinol (Oxf) (1975) 0.89
Triiodothyronine and adipose conversion of OB17 preadipocytes : binding to high affinity sites and effects on fatty acid synthetizing and esterifying enzymes. J Recept Res (1981) 0.89
The Ras GTPase-activating protein (GAP) is an SH3 domain-binding protein and substrate for the Src-related tyrosine kinase, Hck. J Biol Chem (1995) 0.88
Detection of a new de novo mutation at codon 251 of exon 8 of thyroid hormone receptor beta gene in an Italian kindred with resistance to thyroid hormone. J Endocrinol Invest (1998) 0.88
The Src-family kinase Lck can induce STAT3 phosphorylation and DNA binding activity. Cell Signal (1999) 0.88
Cloning and initial characterization of human and mouse Spot 14 genes. FEBS Lett (1997) 0.87
Clinical experience in transvenous and myocardial pacing. Ann N Y Acad Sci (1969) 0.87
The shape of human atrial action potential accounts for different frequency-related changes in vitro. Int J Cardiol (1996) 0.87
Localization of the viral and cellular Src kinases to perinuclear vesicles in fibroblasts. Cell Growth Differ (1992) 0.86
[Cardiac assistance with a pulsed arteriovenous shunt. Experimental study]. Arch Mal Coeur Vaiss (1969) 0.86
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells. Clin Cancer Res (2001) 0.85
Factors influencing triiodothyronine binding properties of liver nuclear receptors. Acta Endocrinol (Copenh) (1976) 0.85
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia (2002) 0.85
Handgrip increases endothelin-1 secretion in normotensive young male offspring of hypertensive parents. J Am Coll Cardiol (1998) 0.84
Cicletanide improves outcome after left circumflex coronary artery occlusion-reperfusion in the dog. J Cardiovasc Pharmacol (1986) 0.84